Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Sarah Waheed, MD, Yazan Alsayed, MD, PhD, Bijay Nair, MD, Jackie Szymonifka, John D Shaughnessy, Jr., Frits van Rhee, MD, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3421.

https://doi.org/10.1182/blood.V114.22.3421.3421

Published: 2009

Journal Articles

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Michele H. Cottler-Fox, MD, Jeff Haessler, MD, Sarah Waheed, MD, Bijay Nair, MD, John Crowley, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3411.

https://doi.org/10.1182/blood.V114.22.3411.3411

Published: 2009

Journal Articles

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Bijay Nair, MD, Monica Grazziutti, PhD, Vanessa Bolejack, PhD, John Crowley, PhD

Blood (2009) 114 (22): 744.

https://doi.org/10.1182/blood.V114.22.744.744

Published: 2009

Journal Articles

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

Bijay Nair, MD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Jackie Szymonifka, Antje Hoering, Ph.D., John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 531.

https://doi.org/10.1182/blood.V114.22.531.531

Published: 2009

Journal Articles

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Yiming Zhou, Lijuan Chen, Bart Barlogie, MD, PhD, Owen Stephens, PhD, Xiaosong Wu, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Sarah Waheed, MD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, John D Shaughnessy, Jr.

Blood (2009) 114 (22): 1804.

https://doi.org/10.1182/blood.V114.22.1804.1804

Published: 2009

Journal Articles

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Damir Herman, PhD, Owen Stephens, PhD, Erming Tian, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, Jeffrey Sawyer, Ph.D., John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 250.

https://doi.org/10.1182/blood.V112.11.250.250

Published: 2008

NARROW

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM).

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM).

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only